Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 324

1.

Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Stage I to II Oral Cavity Cancer.

Cramer JD, Sridharan S, Ferris RL, Duvvuri U, Samant S.

Laryngoscope. 2018 Oct 3. doi: 10.1002/lary.27323. [Epub ahead of print]

PMID:
30284248
2.

PD-L1 mediates dysfunction in activated PD-1+ NK cells in head and neck cancer patients.

Concha-Benavente F, Kansy BA, Moskovitz J, Moy JD, Chandran UR, Ferris RL.

Cancer Immunol Res. 2018 Oct 3. pii: canimm.0062.2018. doi: 10.1158/2326-6066.CIR-18-0062. [Epub ahead of print]

PMID:
30282672
3.

EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer.

Ma W, Concha-Benavente F, Santegoets SJAM, Welters MJP, Ehsan I, Ferris RL, van der Burg SH.

PLoS One. 2018 Sep 7;13(9):e0203402. doi: 10.1371/journal.pone.0203402. eCollection 2018.

4.

Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort.

Geltzeiler M, Bertolet M, Albergotti W, Gleysteen J, Olson B, Persky M, Gross N, Li R, Andersen P, Kim S, Ferris RL, Duvvuri U, Clayburgh D.

Oral Oncol. 2018 Sep;84:82-87. doi: 10.1016/j.oraloncology.2018.07.013. Epub 2018 Jul 22.

PMID:
30115481
5.

Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer.

Albers AE, Qian X, Kaufmann AM, Mytilineos D, Ferris RL, Hoffmann TK, DeLeo AB.

Sci Rep. 2018 Jul 16;8(1):10716. doi: 10.1038/s41598-018-29067-5.

6.

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.

Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O'Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ.

J Clin Invest. 2018 Aug 31;128(9):3926-3940. doi: 10.1172/JCI96519. Epub 2018 Aug 13.

7.

AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features.

Ferris RL, Nikiforov Y, Terris D, Seethala RR, Ridge JA, Angelos P, Duh QY, Wong R, Sabra MM, Fagin JA, McIver B, Bernet VJ, Harrell RM, Busaidy N, Cibas ES, Faquin WC, Sadow P, Baloch Z, Shindo M, Orloff L, Davies L, Randolph GW.

Head Neck. 2018 Sep;40(9):1881-1888. doi: 10.1002/hed.25141. Epub 2018 Jun 26.

PMID:
29947030
8.

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.

Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW.

JAMA Oncol. 2018 Jun 21. doi: 10.1001/jamaoncol.2018.1888. [Epub ahead of print]

PMID:
29931076
9.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.

Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.

PMID:
29884413
10.

P16 as a Prognostic Biomarker for Nonoropharyngeal Squamous Cell Cancers: Avatar or Mirage?

Fakhry C, Ferris RL.

J Natl Cancer Inst. 2018 Jun 5. doi: 10.1093/jnci/djy103. [Epub ahead of print] No abstract available.

PMID:
29878233
11.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.

Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4.

PMID:
29866947
12.

Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.

Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, Zhao X, Bellile E, Hu H, Chen H, Polverini PJ, Chen Q, Young S, Carey TE, Nör JE, Ferris RL, Wolf GT, Sun D, Lei YL.

Clin Cancer Res. 2018 Sep 1;24(17):4242-4255. doi: 10.1158/1078-0432.CCR-17-2807. Epub 2018 May 16.

PMID:
29769207
13.

Oligometastatic status as predictor of survival in metastatic human papillomavirus-positive oropharyngeal carcinoma.

Albergotti WG, Abberbock S, Mathews F, Ferris RL, Johnson JT, Duvvuri U, Kim S.

Head Neck. 2018 Aug;40(8):1685-1690. doi: 10.1002/hed.25171. Epub 2018 May 13.

PMID:
29756301
14.

Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients.

Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava R, Kane LP, Lu B, Ferris RL.

Clin Cancer Res. 2018 Sep 15;24(18):4529-4538. doi: 10.1158/1078-0432.CCR-17-1350. Epub 2018 Apr 30.

PMID:
29712685
15.

Comparison of the seventh and eighth edition american joint committee on cancer oral cavity staging systems.

Cramer JD, Reddy A, Ferris RL, Duvvuri U, Samant S.

Laryngoscope. 2018 Apr 15. doi: 10.1002/lary.27205. [Epub ahead of print]

PMID:
29658104
16.

Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer.

Kim H, Vargo JA, Beriwal S, Clump DA, Ohr JP, Ferris RL, Heron DE, Huq MS, Smith KJ.

Head Neck. 2018 Aug;40(8):1743-1751. doi: 10.1002/hed.25142. Epub 2018 Mar 14.

PMID:
29537684
17.

Erratum to: Staged Reconstruction (Delayed-Immediate) of the Maxillectomy Defect Using CAD/CAM Technology.

Pang JH, Brooke S, Kubik MW, Ferris RL, Dhima M, Hanasono MM, Wang EW, Solari MG.

J Reconstr Microsurg. 2018 Mar 12. doi: 10.1055/s-0038-1635090. [Epub ahead of print] No abstract available.

PMID:
29529687
18.

Immunotherapy for Head and Neck Squamous Cell Carcinoma.

Moskovitz J, Moy J, Ferris RL.

Curr Oncol Rep. 2018 Mar 3;20(2):22. doi: 10.1007/s11912-018-0654-5. Review.

19.

STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer.

Lu S, Concha-Benavente F, Shayan G, Srivastava RM, Gibson SP, Wang L, Gooding WE, Ferris RL.

Oral Oncol. 2018 Mar;78:186-193. doi: 10.1016/j.oraloncology.2018.01.019. Epub 2018 Feb 20.

20.

Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma.

Moskovitz JM, Ferris RL.

J Dent Res. 2018 Jun;97(6):622-626. doi: 10.1177/0022034518759464. Epub 2018 Feb 28.

PMID:
29489423

Supplemental Content

Loading ...
Support Center